END-OF-TREATMENT QUANTITATIVE HBSAG < 500 IU/ML CAN PREDICT SUSTAINED REMISSION AND HBSAG LOSS AFTER DISCONTINUATION OF NUCLEOS(T)IDE ANALOGUES IN CHRONIC HEPATITIS B СтатьяAbdurakhmanov D., Panevkina S., Ibragimov E., Rozina T., Nikulkina E., Mazurchik N.HEPATOLOGY. Том 72. 2020.
EFFICACY OF ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C WITH PEG-IFN ALPHA-2B AND RIBAVIRIN IN COMBINATION WITH METFORMIN IN PATIENTS WITH HCV-1 GENOTYPE AND INSULIN RESISTANCE СтатьяKhafisova O.O., Tarasova O., Mazurchik N., Ogurtsov P.P.HEPATOLOGY. Том 58. 2013.
BOCEPREVIR PLUS PEGINTERFERON ALFA-2B AND RIBAVIRIN IN RUSSIAN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: TREATMENT WEEK 8 INTERIM ANALYSIS СтатьяIsakov V., Nikitin I., Chulanov V.P., Ogurtsov P.P., Lukyanova E., Long J.M., Wahl J., Helmond F.A.HEPATOLOGY. Том 58. 2013.
PREDICT STUDY FINAL RESULTS: EFFICACY AND SAFETY OF 24-WK REGIMEN OF PEGINTERFERON ALFA-2B PLUS WEIGHT-BASED RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 (G1) WITH LOW VIRAL LOAD WHO ACHIEVE RAPID VIRAL RESPONSE СтатьяCraxi A., Zuckerman E., Koutsounas S., Ogurtsov P.P., Chemello L., Maticic M.B., Torras X., Diago M., Tartaglione M., Witthoeft T., Yu X., Chaudhri E.I., Pedicone L., Faruqi R.HEPATOLOGY. Том 50. 2009.
LIVER FUNCTION ACCESSED BY LABORATORY TESTS IN TEST-PILOTS DURING THE 21-DAY LONG DRY IMMERSION СтатьяGimadiev R., Mukhin V., Ogurtsov P., Niiazov A., Polyakov A., Afanas'eva D., Fedyay S.HEPATOLOGY. Том 70. 2019.
EXOSOMAL MIRNAS EXPRESSION LEVELS DYNAMICS IN PLASMA FROM PATIENTS WITH LIVER DISEASES: FROM HEPATITIS THROUGH CIRRHOSIS TO HCC СтатьяPetkevich A., Abramov A., Malinina N., Ogurtsov P.HEPATOLOGY. Том 72. 2020.
THEORETICAL PHYSICS AND ITS NEW APPLICATIONS Сборник материалов конференции3rd International Conference on Theoretical Physics. FEDERAL STATE AUTONOMOUS EDUC INST HIGHER PROFESSIOAL EDUC.
TRANSPLANTATION Сборник материалов конференции14th World Congress of the International-Pancreas-and-Islet-Transplant-Association (IPITA). LIPPINCOTT WILLIAMS & WILKINS.